{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:11:58Z","timestamp":1792620718831,"version":"4.5.0"},"reference-count":50,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Despite increasing evidence supporting the validity and utility of pharmacogenomic (PGx)-guided prescribing, clinical PGx testing in oncology remains limited. However, expanding professional guidelines and recommendations have accelerated PGx implementation efforts in the United States. Given the availability of actionable PGx guidelines for several medications commonly prescribed to patients with cancer, this study evaluated US oncologists' knowledge, attitudes, and perceived barriers regarding PGx-guided medication management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A survey focused on oncology-relevant medications with actionable PGx guidelines, including fluoropyrimidines, thiopurines, irinotecan, and opiates\/antidepressants, was distributed to clinical oncologists in the United States from December 2023 to August 2024 through ASCO Research Survey Pool, the Association of Northern California Oncologists, and regional ASCO-affiliated groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 146 providers completed the survey, most through ASCO (n = 125). Opiates and antidepressants were the most frequently prescribed medications in the previous 6 months (92%), followed by fluoropyrimidines (75%). Nearly all respondents (93%) had heard of PGx, although most were only moderately familiar (57%), and PGx awareness for chemotherapies (92%) was much greater than opiates\/antidepressants (47%). Reported barriers to PGx testing for chemotherapy management included uncertain utility, concerns for treatment delay, and unclear National Comprehensive Cancer Network recommendations, and barriers for opiate\/antidepressant management included uncertain utility, lack of awareness, and uncertainty regarding test ordering and result interpretation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>These findings provide valuable insights into the perspectives of oncologists on implementing PGx testing; however, awareness and utilization were higher than previously reported. Importantly, the identified implementation barriers for oncology are both actionable and timely, particularly given the evolving updates to drug labels and professional guidelines supporting PGx testing for medications relevant to patients with cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-26-00353","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:59:13Z","timestamp":1785873553000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Knowledge and Attitudes on Germline Pharmacogenomic Testing Among Clinical Oncologists"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3383-5932","authenticated-orcid":true,"given":"Mattie","family":"Monroe","sequence":"first","affiliation":[{"name":"Department of Genetics, Stanford University School of Medicine, Palo Alto, CA"},{"name":"Department of Genetics, Rady Children's Health\u2014San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5894-7390","authenticated-orcid":true,"given":"Hetanshi","family":"Naik","sequence":"additional","affiliation":[{"name":"Department of Genetics, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2513-7025","authenticated-orcid":true,"given":"James M.","family":"Ford","sequence":"additional","affiliation":[{"name":"Department of Genetics, Stanford University School of Medicine, Palo Alto, CA"},{"name":"Department of Medicine, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2414-9312","authenticated-orcid":true,"given":"Michelle","family":"Whirl-Carrillo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Data Science, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri E.","family":"Klein","sequence":"additional","affiliation":[{"name":"Departments of Biomedical Data Science, Medicine &amp; Genetics, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0501-1035","authenticated-orcid":true,"given":"Daniel L.","family":"Hertz","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5720-1864","authenticated-orcid":true,"given":"Stuart A.","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-020-00181-w"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01841-4"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1048"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.279"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2350"},{"key":"e_1_3_6_7_2","volume-title":"Table of Pharmacogenetic Associations","author":"United States Food and Drug Administration (FDA)","year":"2026","unstructured":"United States Food and Drug Administration (FDA): Table of Pharmacogenetic Associations, 2026"},{"key":"e_1_3_6_8_2","volume-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC): ClinPGx","year":"2026","unstructured":"Clinical Pharmacogenetics Implementation Consortium (CPIC): ClinPGx, 2026"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32833c6107"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30686-7"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13967"},{"key":"e_1_3_6_12_2","article-title":"Real-world impact of an In-House dihydropyrimidine dehydrogenase (DPYD) genotype test on fluoropyrimidine dosing, toxicities, and hospitalizations at a multisite cancer center","author":"Nguyen DG","unstructured":"Nguyen DG, Morris SA, Hamilton A, et al: Real-world impact of an In-House dihydropyrimidine dehydrogenase (DPYD) genotype test on fluoropyrimidine dosing, toxicities, and hospitalizations at a multisite cancer center. JCO Precis Oncol 10.1200\/PO.23.00623","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2024.05.015"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00874"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231167554"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01609"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2463"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13672"},{"key":"e_1_3_6_19_2","volume-title":"ASCO clinical notice reaffirming the necessity of DPYD genotyping before fluoropyrimidine treatment","author":"American Society of Clinical Oncology (ASCO)","year":"2025","unstructured":"American Society of Clinical Oncology (ASCO): ASCO clinical notice reaffirming the necessity of DPYD genotyping before fluoropyrimidine treatment. ASCO Connection, 2025. https:\/\/connection.asco.org\/do\/asco-clinical-notice-reaffirming-necessity-dpyd-x00a0-genotyping-fluoropyrimidine"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0029"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00553"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-019-0540-0"},{"key":"e_1_3_6_23_2","unstructured":"European Medicines Agency: EMA recommendations on DPD testing prior to treatment with fluorouracil capecitabine tegafur and flucytosine 2020"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09171-6"},{"key":"e_1_3_6_25_2","volume-title":"CPIC Genes-Drugs","author":"Clinical Pharmacogenomics Implementation Consortium (CPIC)","year":"2026","unstructured":"Clinical Pharmacogenomics Implementation Consortium (CPIC): CPIC Genes-Drugs, 2026"},{"key":"e_1_3_6_26_2","volume-title":"Patient Quality of Life Coalition: Key Findings Summary: Opioid Access Research Project","author":"Network ACSCA","year":"2018","unstructured":"Network ACSCA: Patient Quality of Life Coalition: Key Findings Summary: Opioid Access Research Project, 2018"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.2944"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06170-4"},{"key":"e_1_3_6_29_2","volume-title":"Adult Cancer Pain, NCCN Clinical Practice Guidelines in Oncology","author":"Network NCC","year":"2024","unstructured":"Network NCC: Adult Cancer Pain, NCCN Clinical Practice Guidelines in Oncology, 2024"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0001"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13737"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s10038-020-0723-0"},{"key":"e_1_3_6_33_2","unstructured":"ClinPGx: https:\/\/www.clinpgx.org\/"},{"key":"e_1_3_6_34_2","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024","unstructured":"R Core Team: R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2024"},{"key":"e_1_3_6_35_2","volume-title":"U.S. Physician Workforce Data Dashboard","author":"Colleges AAoM","year":"2023","unstructured":"Colleges AAoM: U.S. Physician Workforce Data Dashboard, 2023"},{"key":"e_1_3_6_36_2","unstructured":"Hammond B: OHSU to pay $1 million promises change to settle lawsuit from widow of cancer patient. The Oregonian\/Oregon Live 2022"},{"key":"e_1_3_6_37_2","volume-title":"SWOG Cancer Research Network","author":"SWOG Cancer Research Network","year":"2025","unstructured":"SWOG Cancer Research Network: SWOG Cancer Research Network, 2025"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219896395"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-021-00575-x"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S62918"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08674-1"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00776"},{"key":"e_1_3_6_43_2","volume-title":"Safety Labeling Update for Capecitabine and Fluorouracil (5-FU) on Risks Associated with Dihydropyrimidine Dehydrogenase (DPD) Deficiency","author":"Administration USFaD","year":"2025","unstructured":"Administration USFaD: Safety Labeling Update for Capecitabine and Fluorouracil (5-FU) on Risks Associated with Dihydropyrimidine Dehydrogenase (DPD) Deficiency, 2025"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2978"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.87"},{"key":"e_1_3_6_46_2","volume-title":"Association for Molecular Pathology Position Statement: Best Practices for Clinical Pharmacogenomic Testing","author":"Association for Molecular Pathology","year":"2019","unstructured":"Association for Molecular Pathology: Association for Molecular Pathology Position Statement: Best Practices for Clinical Pharmacogenomic Testing, 2019"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.911"},{"key":"e_1_3_6_48_2","article-title":"Reducing fluorouracil doses in patients with partial dihydropyrimidine dehydrogenase deficiency is a treatment safety strategy, not a panacea of precision dosing","author":"Hertz DL","unstructured":"Hertz DL, Venook AP: Reducing fluorouracil doses in patients with partial dihydropyrimidine dehydrogenase deficiency is a treatment safety strategy, not a panacea of precision dosing. JCO Precis Oncol 10.1200\/PO-25-00440","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_6_49_2","article-title":"Precision treatment of patients with GI cancer using pre-emptive DPYD genotyping\/phenotyping plus pharmacokinetic-guided dosing of 5-Fluorouracil","author":"Fiebrich-Westra HB","unstructured":"Fiebrich-Westra HB, Haroun C, van der Galien R, et al: Precision treatment of patients with GI cancer using pre-emptive DPYD genotyping\/phenotyping plus pharmacokinetic-guided dosing of 5-Fluorouracil. JCO Precis Oncol 10.1200\/PO-25-00062","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02629"},{"key":"e_1_3_6_51_2","doi-asserted-by":"crossref","unstructured":"Ho TT Smith DM Aquilante CL et al: A guide for implementing DPYD genotyping for systemic flouropyrimidines into clinical practice. Clin Pharmacol Ther 117:1194-1208 2025","DOI":"10.1002\/cpt.3567"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-26-00353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:59:22Z","timestamp":1785873562000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-26-00353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1200\/PO-26-00353"],"URL":"https:\/\/doi.org\/10.1200\/po-26-00353","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2600353"}}